| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. (NCT06059469) | Jules Bordet Institute | 2022-05-30 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| RTX-224 Monotherapy in Patients With Solid Tumors (NCT05219578) | Rubius Therapeutics | 2022-01-12 |
| Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer (NCT05402722) | Beijing 302 Hospital | 2022-01-01 |
| Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer (NCT05541367) | Tongji Hospital | 2021-12-31 |
| Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (NCT04674306) | George T. Budd | 2021-10-01 |
| PhI to Solid Tumors and PhII to Locally Advanced or mTNBC (NCT05390710) | Laekna Limited | 2021-06-12 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (NCT04799249) | G1 Therapeutics, Inc. | 2021-05-14 |
| A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer (NCT04683679) | Memorial Sloan Kettering Cancer Center | 2021-04-21 |
| TH1902 in Patients With Advanced Solid Tumors (NCT04706962) | Theratechnologies | 2021-03-04 |
| Talazoparib Maintenance Therapy in Triple-negative Breast Cancer (NCT04755868) | Yonsei University | 2021-03-01 |
| First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients (NCT04537286) | Fudan University | 2020-08-25 |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (NCT03199040) | Washington University School of Medicine | 2019-07-23 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313) | Calithera Biosciences, Inc | 2019-05-20 |
| Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers (NCT03911973) | Kari Wisinski | 2019-04-17 |
| Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (NCT03719326) | Arcus Biosciences, Inc. | 2018-10-15 |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NCT03207867) | Novartis Pharmaceuticals | 2017-08-28 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) (NCT03057600) | Calithera Biosciences, Inc | 2017-05-01 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (NCT01042379) | QuantumLeap Healthcare Collaborative | 2010-03-01 |
| An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC) (NCT07536815) | CytoDyn, Inc. | |